RVNC vs. ARDX, NRIX, KNSA, RCUS, MRVI, OCUL, ARVN, CALT, DAWN, and PRAX
Should you be buying Revance Therapeutics stock or one of its competitors? The main competitors of Revance Therapeutics include Ardelyx (ARDX), Nurix Therapeutics (NRIX), Kiniksa Pharmaceuticals (KNSA), Arcus Biosciences (RCUS), Maravai LifeSciences (MRVI), Ocular Therapeutix (OCUL), Arvinas (ARVN), Calliditas Therapeutics AB (publ) (CALT), Day One Biopharmaceuticals (DAWN), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry.
Revance Therapeutics vs.
Ardelyx (NASDAQ:ARDX) and Revance Therapeutics (NASDAQ:RVNC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, community ranking, risk, valuation, profitability, institutional ownership and earnings.
In the previous week, Revance Therapeutics had 17 more articles in the media than Ardelyx. MarketBeat recorded 27 mentions for Revance Therapeutics and 10 mentions for Ardelyx. Ardelyx's average media sentiment score of 0.79 beat Revance Therapeutics' score of 0.11 indicating that Ardelyx is being referred to more favorably in the media.
Ardelyx currently has a consensus target price of $9.25, suggesting a potential upside of 64.59%. Revance Therapeutics has a consensus target price of $8.39, suggesting a potential upside of 154.88%. Given Revance Therapeutics' higher possible upside, analysts plainly believe Revance Therapeutics is more favorable than Ardelyx.
Ardelyx has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. Comparatively, Revance Therapeutics has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.
Ardelyx has a net margin of -28.82% compared to Revance Therapeutics' net margin of -74.67%. Revance Therapeutics' return on equity of 0.00% beat Ardelyx's return on equity.
58.9% of Ardelyx shares are owned by institutional investors. Comparatively, 97.7% of Revance Therapeutics shares are owned by institutional investors. 5.9% of Ardelyx shares are owned by insiders. Comparatively, 5.1% of Revance Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Ardelyx has higher earnings, but lower revenue than Revance Therapeutics. Ardelyx is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks.
Ardelyx received 130 more outperform votes than Revance Therapeutics when rated by MarketBeat users. Likewise, 67.56% of users gave Ardelyx an outperform vote while only 61.04% of users gave Revance Therapeutics an outperform vote.
Summary
Ardelyx beats Revance Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Revance Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Revance Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:RVNC) was last updated on 1/15/2025 by MarketBeat.com Staff
Free RVNC Stock Alerts